Abstract

In this issue of Blood, Casu et al report on results from their studies on potential therapeutic options to restrict iron as a treatment of 2 differing blood disorders: the anemia and iron overload associated with b-thalassemia, and the erythrocytosis associated with polycythemia vera (PV). They examine the use of derivatives of hepcidin, a 25-amino acid peptide secreted by the liver, which is widely accepted as the "iron stores" regulator.(1)

Authors	Subramaniam, V. Nathan
Journal	BLOOD
Pages	153-154
Volume	128
Date	1/07/2016
Grant ID
Funding Body
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1182/blood-2016-05-716043
	Download Article